NSAIDs: the emperor's new dogma?


The spectacular marketing success of the selective cyclooxygenase 2 (COX-2) inhibitors is largely based on efficacy comparable with conventional non-steroidal anti-inflammatory drugs (NSAIDs) with vastly improved gastrointestinal safety. The additional key to the marketing success is the purity and simplicity of the message-that is, COX-1 inhibition causes the gastrointestinal side effects of NSAIDs (COX-1 dogma) while COX-2 blocking confers the therapeutic benefits (COX-2 dogma). Adherence to the COX dogmas with development of COX-2 selective agents has undoubtedly benefited many patients, but ironically their scientific basis is now seriously challenged by experimentation.

Cite this paper

@article{Bjarnason2003NSAIDsTE, title={NSAIDs: the emperor's new dogma?}, author={Ingvar T Bjarnason and Koji Takeuchi and Robert Simpson}, journal={Gut}, year={2003}, volume={52 9}, pages={1376-8} }